Core Viewpoint - The announcement highlights the acceptance of the New Drug Application (NDA) for the influenza drug, Madaxanovir Granules (Xianlinda), by the National Medical Products Administration (NMPA) in China, marking a significant milestone for the company and the industry in pediatric antiviral treatments [1] Company Summary - The company has collaborated with Jiaxing Andikang Biotechnology Co., Ltd. for the development of Madaxanovir Granules [1] - This drug is specifically designed for treating uncomplicated Type A and B influenza in children aged 2 to 11 years [1] - Madaxanovir Granules is noted as the first innovative antiviral drug targeting pediatric patients in China to successfully complete Phase III clinical trials and submit for market approval [1] Industry Summary - The acceptance of the NDA represents a breakthrough in the antiviral drug market for children in China, addressing a significant unmet medical need [1] - The development of pediatric-specific antiviral treatments is becoming increasingly important in the healthcare landscape, particularly in response to seasonal influenza outbreaks [1]
先声药业：玛氘诺沙韦颗粒新药上市申请获国家药品监督管理局受理